Physician profile
Katherine Stemmer
NPI 1750930483
$1,309.85
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $222.91 | 2021 | |
| Lilly USA, LLC | $175.36 | 2021 | |
| Amgen INC. | $156.91 | 2021-2022 | |
| Novo Nordisk INC | $131.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $91.84 | 2021 | |
| Merck Sharp & Dohme LLC | $91.54 | 2021 | |
| Amarin Pharma, INC. | $66.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.28 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.48 | 2021 | |
| Genentech USA, INC. | $36.78 | 2021 | |
| Collegium Pharmaceutical, INC. | $29.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.97 | 2022 | |
| Forte Bio-Pharma LLC | $25.70 | 2021 | |
| Abbvie INC. | $16.17 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2021 | |
| Optinose US, INC. | $12.16 | 2021 | |
| Glaxosmithkline, LLC. | $11.64 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Stemmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.